TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele

British Journal of Haematology

Volumn 156, Issue 1, 2012, Pages 67-75

  Bacher, Ulrike ^a   Weissmann, Sandra ^b   Kohlmann, Alexander ^b   Schindela, Sonja ^b   Alpermann, Tamara ^b   Schnittger, Susanne ^b   Kern, Wolfgang ^b   Haferlach, Torsten ^b   Haferlach, Claudia ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Acute myeloid leukaemia; Fluorescence in situ hybridization; Myelodysplastic syndromes; TET2 deletion; TET2 mutations

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HAPLOINSUFFICIENCY; HEMATOLOGIC MALIGNANCY; HUMAN; INTERPHASE; MAJOR CLINICAL STUDY; MALE; METAPHASE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SINGLE NUCLEOTIDE POLYMORPHISM; TET2 GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; HAPLOINSUFFICIENCY; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; PROTO-ONCOGENE PROTEINS;

EID: 83555174295     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08911.x     Document Type: Article

References (26)

1. Bacher, U., Haferlach, T., Schoch, C., Kern, W. & Schnittger, S. (2006) Implications of NRAS mutations in AML: a study of 2502 patients. Blood, 107, 3847-3853.
2. Bacher, U., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood, 111, 2527-2537.
3. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., Vainchenker, W. & Bernard, O.A. (2009) Mutation in TET2 in myeloid cancers. The New England journal of medicine, 360, 2289-2301.
4. Grimwade, D., Hills, R., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A., Wheatley, K., Harrison, C., Burnett, A. & On behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5876 younger adult patients treated in the UK Medical Research Council trials. Blood, 116, 354-365.
5. Haferlach, C., Bacher, U., Kohlmann, A., Schindela, S., Alpermann, T., Kern, W., Schnittger, S. & Haferlach, T. (2011) CDKN1B encoding the cyclin-dependent kinase inhibitor 1B (p27) is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia. Haematologica, 96, 829-836.
6. Jankowska, A.M., Szpurka, H., Tiu, R.V., Makishima, H., Afable, M., Huh, J., O'Keefe, C.L., Ganetzky, R., McDevitt, M.A. & Maciejewski, J.P. (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood, 113, 6403-6410.
7. Kohlmann, A., Haschke-Becher, E., Wimmer, B., Huber-Wechselberger, A., Meyer-Monard, S., Huxol, H., Siegler, U., Rossier, M., Matthes, T., Rebsamen, M., Chiappe, A., Diemand, A., Rauhut, S., Johnson, A., Liu, W.M., Williams, P.M., Wieczorek, L. & Haferlach, T. (2008a) Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study. Clinical chemistry, 54, 1705-1715.
8. Kohlmann, A., Kipps, T.J., Rassenti, L.Z., Downing, J.R., Shurtleff, S.A., Mills, K.I., Gilkes, A.F., Hofmann, W.K., Basso, G., Dell'orto, M.C., Foa, R., Chiaretti, S., De Vos, J., Rauhut, S., Papenhausen, P.R., Hernandez, J.M., Lumbreras, E., Yeoh, A.E., Koay, E.S., Li, R., Liu, W.M., Williams, P.M., Wieczorek, L. & Haferlach, T. (2008b) An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British journal of haematology, 142, 802-807.
9. Kohlmann, A., Grossmann, V., Klein, H.U., Schindela, S., Weiss, T., Kazak, B., Dicker, F., Schnittger, S., Dugas, M., Kern, W., Haferlach, C. & Haferlach, T. (2010) Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Journal of clinical oncology, 28, 3858-3865.
10. Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.N., Beyne-Rauzy, O., Stamatoulas, A., Dreyfus, F., Ifrah, N., de Botton, S., Vainchenker, W., Bernard, O.A., Birnbaum, D., Fontenay, M. & Solary, E. (2009a) TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 94, 1676-1681.
11. Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguie, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., Vey, N., Hunault-Berger, M., Fenaux, P., Mansat-De, M.V., Delabesse, E., Guardiola, P., Lacombe, C., Vainchenker, W., Preudhomme, C., Dreyfus, F., Bernard, O.A., Birnbaum, D. & Fontenay, M. (2009b) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 114, 3285-3291.
12. Langemeijer, S.M., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A.G., Raymakers, R.A., Kamping, E.J., Verhoef, G.E., Verburgh, E., Hagemeijer, A., Vandenberghe, P., de Witte, T., van der Reijden, B.A. & Jansen, J.H. (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature genetics, 41, 838-842.
13. Mallo, M., Osca, G., Solorzano, J., Arenillas, L., Florensa, L. & Sole, F. (2010) TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica, 95, 1798-1800.
14. Metzeler, K.H., Maharry, K., Radmacher, M.D., Mrozek, K., Margeson, D., Becker, H., Curfman, J., Holland, K.B., Schwind, S., Whitman, S.P., Wu, Y.Z., Blum, W., Powell, B.L., Carter, T.H., Wetzler, M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2011) TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: a Cancer and Leukemia Group B Study. Journal of clinical oncology, 29, 1373-1381.
15. Nibourel, O., Kosmider, O., Cheok, M., Boissel, N., Renneville, A., Philippe, N., Dombret, H., Dreyfus, F., Quesnel, B., Geffroy, S., Quentin, S., Roche-Lestienne, C., Cayuela, J.M., Roumier, C., Fenaux, P., Vainchenker, W., Bernard, O.A., Soulier, J., Fontenay, M. & Preudhomme, C. (2010) Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 116, 1132-1135.
16. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C.M., Serve, H., Buchner, T., Haferlach, T. & Hiddemann, W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66.
17. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-3739.
18. Schnittger, S., Bacher, U., Kern, W., Schröder, M., Haferlach, T. & Schoch, C. (2006) Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia, 20, 2195-2197.
19. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. Blood, 114, 2220-2231.
20. Schnittger, S., Haferlach, C., Ulke, M., Alpermann, T., Kern, W. & Haferlach, T. (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60years and unmutated NPM1 status. Blood, 116, 5486-5496.
21. Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C. & Haferlach, T. (2011) RUNX1 mutations are frequent in de novo AML with non complex karyotype and confer an unfavourable prognosis. Blood, 117, 2348-2357.
22. Schoch, C., Schnittger, S., Bursch, S., Gerstner, D., Hochhaus, A., Berger, U., Hehlmann, R., Hiddemann, W. & Haferlach, T. (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia, 16, 53-59.
23. Smith, A.E., Mohamedali, A.M., Kulasekararaj, A., Lim, Z., Gaken, J., Lea, N.C., Przychodzen, B., Mian, S.A., Nasser, E.E., Shooter, C., Westwood, N.B., Strupp, C., Gattermann, N., Maciejewski, J.P., Germing, U. & Mufti, G.J. (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood, 116, 3923-3932.
24. Tefferi, A., Pardanani, A., Lim, K.H., bdel-Wahab, O., Lasho, T.L., Patel, J., Gangat, N., Finke, C.M., Schwager, S., Mullally, A., Li, C.Y., Hanson, C.A., Mesa, R., Bernard, O., Delhommeau, F., Vainchenker, W., Gilliland, D.G. & Levine, R.L. (2009) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia, 23, 905-911.
25. Viguie, F., Aboura, A., Bouscary, D., Ramond, S., Delmer, A., Tachdjian, G., Marie, J.P. & Casadevall, N. (2005) Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia, 19, 1411-1415.
26. Weisser, M., Kern, W., Schoch, C., Hiddemann, W., Haferlach, T. & Schnittger, S. (2005) Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica, 90, 881-889.